Beta Bionics, Inc. (BBNX) Stock Forecast & Price Target

Compare

52 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BBNX Analyst Ratings

Moderate Buy

6 Buy

3 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Beta

Bionics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BBNX Stock 12 Month Forecast

Average Price Target

$22.89

▲(70.06% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Beta Bionics, Inc. in the last 3 months. The average price target is $22.89 with a high forecast of $32.00 and a low forecast of $14.00. The average price target represents a 70.06% change from the last price of $13.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","33":"$33","15.75":"$15.75","21.5":"$21.5","27.25":"$27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.75,21.5,27.25,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,15.107692307692307,16.515384615384615,17.923076923076923,19.33076923076923,20.73846153846154,22.146153846153844,23.553846153846152,24.96153846153846,26.369230769230768,27.776923076923076,29.184615384615384,30.592307692307692,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,14.406923076923077,15.113846153846154,15.82076923076923,16.527692307692305,17.234615384615385,17.94153846153846,18.64846153846154,19.355384615384615,20.06230769230769,20.76923076923077,21.476153846153846,22.183076923076925,{"y":22.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.7,13.723076923076922,13.746153846153845,13.769230769230768,13.792307692307691,13.815384615384614,13.838461538461537,13.861538461538462,13.884615384615385,13.907692307692308,13.930769230769231,13.953846153846154,13.976923076923077,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.81,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$32.00

Average Price Target$22.89

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jeff Johnson

Robert W. Baird

$28→$14

Hold

4.01%

Upside

Reiterated

02/18/26

Beta Bionics price target lowered to $14 from $28 at BairdBeta Bionics price target lowered to $14 from $28 at Baird

Jonathan Block

Stifel Nicolaus

$25→$22

Buy

63.45%

Upside

Reiterated

02/18/26

Beta Bionics price target lowered to $22 from $25 at StifelBeta Bionics price target lowered to $22 from $25 at Stifel

Danielle Antalffy

UBS

$24

Buy

78.31%

Upside

Reiterated

02/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Exact Sciences (NASDAQ: EXAS) and Glaukos (NYSE: GKOS)

Frank Takkinen

Lake Street

$20

Buy

48.59%

Upside

Reiterated

02/18/26

Beta Bionics price target lowered to $20 from $40 at Lake StreetBeta Bionics price target lowered to $20 from $40 at Lake Street

Matthew O'Brien

Piper Sandler

$32

Buy

137.74%

Upside

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Medline, Inc. Class A (NASDAQ: MDLN) and Palatin Technologies (NYSE MKT: PTN)

Mathew Blackman

TD Cowen

$17→$16

Hold

18.87%

Upside

Reiterated

02/17/26

Hold Rating Maintained as In-Line Results and Improving Margins Offset Near-Term Prescription Headwinds

Travis Steed

Bank of America Securities

$28

Hold

108.02%

Upside

Reiterated

02/17/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Masimo (NASDAQ: MASI), Janux Therapeutics Inc (NASDAQ: JANX) and Beta Bionics, Inc. (NASDAQ: BBNX)

Richard Newitter

Truist Financial

$37→$25

Buy

85.74%

Upside

Reiterated

02/02/26

Analysts Conflicted on These Healthcare Names: UnitedHealth (NYSE: UNH), CytomX Therapeutics (NASDAQ: CTMX) and Beta Bionics, Inc. (NASDAQ: BBNX)

David Roman

Goldman Sachs

$33→$25

Buy

85.74%

Upside

Reiterated

01/15/26

Beta Bionics price target lowered to $25 from $33 at Goldman SachsBeta Bionics price target lowered to $25 from $33 at Goldman Sachs

Mike Kratky

Leerink Partners

$28

Buy

108.02%

Upside

Reiterated

09/12/25

Leerink Partners Sticks to Their Buy Rating for Beta Bionics, Inc. (BBNX)

Michael Polark

Wolfe Research

$20

Buy

48.59%

Upside

Initiated

05/29/25

Wolfe Research Initiates a Buy Rating on Beta Bionics, Inc. (BBNX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jeff Johnson

Robert W. Baird

$28→$14

Hold

4.01%

Upside

Reiterated

02/18/26

Beta Bionics price target lowered to $14 from $28 at BairdBeta Bionics price target lowered to $14 from $28 at Baird

Jonathan Block

Stifel Nicolaus

$25→$22

Buy

63.45%

Upside

Reiterated

02/18/26

Beta Bionics price target lowered to $22 from $25 at StifelBeta Bionics price target lowered to $22 from $25 at Stifel

Danielle Antalffy

UBS

$24

Buy

78.31%

Upside

Reiterated

02/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Exact Sciences (NASDAQ: EXAS) and Glaukos (NYSE: GKOS)

Frank Takkinen

Lake Street

$20

Buy

48.59%

Upside

Reiterated

02/18/26

Beta Bionics price target lowered to $20 from $40 at Lake StreetBeta Bionics price target lowered to $20 from $40 at Lake Street

Matthew O'Brien

Piper Sandler

$32

Buy

137.74%

Upside

Reiterated

02/18/26

Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Medline, Inc. Class A (NASDAQ: MDLN) and Palatin Technologies (NYSE MKT: PTN)

Mathew Blackman

TD Cowen

$17→$16

Hold

18.87%

Upside

Reiterated

02/17/26

Hold Rating Maintained as In-Line Results and Improving Margins Offset Near-Term Prescription Headwinds

Travis Steed

Bank of America Securities

$28

Hold

108.02%

Upside

Reiterated

02/17/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Masimo (NASDAQ: MASI), Janux Therapeutics Inc (NASDAQ: JANX) and Beta Bionics, Inc. (NASDAQ: BBNX)

Richard Newitter

Truist Financial

$37→$25

Buy

85.74%

Upside

Reiterated

02/02/26

Analysts Conflicted on These Healthcare Names: UnitedHealth (NYSE: UNH), CytomX Therapeutics (NASDAQ: CTMX) and Beta Bionics, Inc. (NASDAQ: BBNX)

David Roman

Goldman Sachs

$33→$25

Buy

85.74%

Upside

Reiterated

01/15/26

Beta Bionics price target lowered to $25 from $33 at Goldman SachsBeta Bionics price target lowered to $25 from $33 at Goldman Sachs

Mike Kratky

Leerink Partners

$28

Buy

108.02%

Upside

Reiterated

09/12/25

Leerink Partners Sticks to Their Buy Rating for Beta Bionics, Inc. (BBNX)

Michael Polark

Wolfe Research

$20

Buy

48.59%

Upside

Initiated

05/29/25

Wolfe Research Initiates a Buy Rating on Beta Bionics, Inc. (BBNX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beta Bionics, Inc.

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+18.04%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +18.04% per trade.

1 Year

Mike KratkyLeerink Partners

Success Rate

2/5 ratings generated profit

Average Return

-13.92%

reiterated a buy rating 5 months ago

Copying Mike Kratky's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -13.92% per trade.

2 Years

xxx

Success Rate

2/5 ratings generated profit

Average Return

-13.92%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -13.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBNX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BBNX has received 17 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. BBNX average Analyst price target in the past 3 months is 22.89.

Each month's total comprises the sum of three months' worth of ratings.

BBNX Financial Forecast

BBNX Earnings Forecast

Next quarter’s earnings estimate for BBNX is -$0.49 with a range of -$0.62 to -$0.33. The previous quarter’s EPS was -$0.30. BBNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BBNX has Performed in-line its overall industry.

BBNX Sales Forecast

Next quarter’s sales forecast for BBNX is $26.90M with a range of $25.90M to $28.93M. The previous quarter’s sales results were $32.12M. BBNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BBNX has Performed in-line its overall industry.

BBNX Stock Forecast FAQ

What is BBNX’s average 12-month price target, according to analysts?

Based on analyst ratings, Beta Bionics, Inc.’s 12-month average price target is 22.89.

What is BBNX’s upside potential, based on the analysts’ average price target?

Beta Bionics, Inc. has 70.06% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BBNX a Buy, Sell or Hold?

Beta Bionics, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Beta Bionics, Inc.’s price target?

The average price target for Beta Bionics, Inc. is 22.89. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $32.00 ,the lowest forecast is $14.00. The average price target represents 70.06% Increase from the current price of $13.46.

What do analysts say about Beta Bionics, Inc.?

Beta Bionics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of BBNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Beta Bionics, Inc. (BBNX) Stock Forecast & Price Target

BBNX Analyst Ratings

BBNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Beta Bionics, Inc.

BBNX Analyst Recommendation Trends

BBNX Financial Forecast

BBNX Earnings Forecast

BBNX Sales Forecast

BBNX Stock Forecast FAQ

Detailed List of Analyst Forecasts